226 related articles for article (PubMed ID: 2849601)
1. Effects of azole antifungals in vitro on host/parasite interactions relevant to Candida infections.
Odds FC; Webster CE
J Antimicrob Chemother; 1988 Oct; 22(4):473-81. PubMed ID: 2849601
[TBL] [Abstract][Full Text] [Related]
2. [Anti-Candida activities of azole antifungals in the presence of lysozyme in vitro].
Abe S; Tansho S; Perera PD; Hiratani T; Nishiyama Y; Uchida K; Yamaguchi H
Nihon Ishinkin Gakkai Zasshi; 1998; 39(2):103-7. PubMed ID: 9580036
[TBL] [Abstract][Full Text] [Related]
3. Effects of imidazole- and triazole-derivative antifungal compounds on the growth and morphological development of Candida albicans hyphae.
Odds FC; Cockayne A; Hayward J; Abbott AB
J Gen Microbiol; 1985 Oct; 131(10):2581-9. PubMed ID: 2999296
[TBL] [Abstract][Full Text] [Related]
4. In vitro effects of fluconazole (UK-49,858) and ketoconazole on mouse lymphocyte proliferation and on Candida blastospore destruction by human polymorphonuclear leukocytes.
Senior DS; Shaw JT
Int J Immunopharmacol; 1988; 10(2):169-73. PubMed ID: 2836326
[TBL] [Abstract][Full Text] [Related]
5. Azole resistance in Candida albicans.
Smith KJ; Warnock DW; Kennedy CT; Johnson EM; Hopwood V; Van Cutsem J; Vanden Bossche H
J Med Vet Mycol; 1986 Apr; 24(2):133-44. PubMed ID: 3014106
[TBL] [Abstract][Full Text] [Related]
6. Antifungal relative inhibition factors: BAY l-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents.
Odds FC; Webster CE; Abbott AB
J Antimicrob Chemother; 1984 Aug; 14(2):105-14. PubMed ID: 6094418
[TBL] [Abstract][Full Text] [Related]
7. Lack of in vitro resistance of Candida albicans to ketoconazole, itraconazole and clotrimazole in women treated for recurrent vaginal candidiasis.
Fong IW; Bannatyne RM; Wong P
Genitourin Med; 1993 Feb; 69(1):44-6. PubMed ID: 8383096
[TBL] [Abstract][Full Text] [Related]
8. Candida albicans adhesion to and invasion and damage of vaginal epithelial cells: stage-specific inhibition by clotrimazole and bifonazole.
Wächtler B; Wilson D; Hube B
Antimicrob Agents Chemother; 2011 Sep; 55(9):4436-9. PubMed ID: 21746947
[TBL] [Abstract][Full Text] [Related]
9. Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis.
Lynch ME; Sobel JD; Fidel PL
J Med Vet Mycol; 1996; 34(5):337-9. PubMed ID: 8912167
[TBL] [Abstract][Full Text] [Related]
10. [Comparative action of 8 azole derivatives against Candida albicans: fungistatic action and cytologic study by scanning electron microscopy].
Mallie M; Jouvert S; Bastide M; Montes B; Lebecq JC; Bastide JM
Pathol Biol (Paris); 1988 May; 36(5):575-80. PubMed ID: 3043361
[TBL] [Abstract][Full Text] [Related]
11. [Effect of synthetic antifungal drugs on the adherence of Candida albicans to the mouth mucosa epithelium in vitro].
Macura AB; Dwernicka B
Med Dosw Mikrobiol; 1989; 41(1):67-70. PubMed ID: 2668662
[TBL] [Abstract][Full Text] [Related]
12. Effect of amphotericin B, fluconazole and itraconazole on intracellular Candida albicans and germ tube development in macrophages.
Van 't Wout JW; Meynaar I; Linde I; Poell R; Mattie H; Van Furth R
J Antimicrob Chemother; 1990 May; 25(5):803-11. PubMed ID: 2165051
[TBL] [Abstract][Full Text] [Related]
13. Action of fluconazole (UK-49,858) in relation to other systemic antifungal azoles.
Hughes CE; Beggs WH
J Antimicrob Chemother; 1987 Feb; 19(2):171-4. PubMed ID: 3032882
[TBL] [Abstract][Full Text] [Related]
14. Enhanced anti-Candida activity of neutrophils and azole antifungal agents in the presence of lactoferrin-related compounds.
Wakabayashi H; Okutomi T; Abe S; Hayasawa H; Tomita M; Yamaguchi H
Adv Exp Med Biol; 1998; 443():229-37. PubMed ID: 9781363
[TBL] [Abstract][Full Text] [Related]
15. Activities of fluconazole (UK 49,858) and ketoconazole against ketoconazole-susceptible and -resistant Candida albicans.
Hughes CE; Bennett RL; Tuna IC; Beggs WH
Antimicrob Agents Chemother; 1988 Feb; 32(2):209-12. PubMed ID: 2834995
[TBL] [Abstract][Full Text] [Related]
16. Suppression of ATP in Candida albicans by imidazole and derivative antifungal agents.
Odds FC; Cheesman SL; Abbott AB
Sabouraudia; 1985 Dec; 23(6):415-24. PubMed ID: 3913012
[TBL] [Abstract][Full Text] [Related]
17. In vitro antifungal activity of sertaconazole compared with nine other drugs against 250 clinical isolates of dermatophytes and Scopulariopsis brevicaulis.
Carrillo-Muñoz AJ; Guglietta A; Palacín C; Casals J; del Valle O; Guardià C; Rodríguez V; Quindós G
Chemotherapy; 2004 Dec; 50(6):308-13. PubMed ID: 15608448
[TBL] [Abstract][Full Text] [Related]
18. Modification of polymorphonuclear leucocyte function by imidazoles.
Rowan-Kelly B; Ferrante A; Thong YH
Int J Immunopharmacol; 1984; 6(4):389-93. PubMed ID: 6090323
[TBL] [Abstract][Full Text] [Related]
19. Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo.
Rogers TE; Galgiani JN
Antimicrob Agents Chemother; 1986 Sep; 30(3):418-22. PubMed ID: 3022641
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibilities of clinical yeast isolates to the new antifungal eberconazole compared with their susceptibilities to clotrimazole and ketoconazole.
Torres-Rodríguez JM; Mendez R; López-Jodra O; Morera Y; Espasa M; Jimenez T; Lagunas C
Antimicrob Agents Chemother; 1999 May; 43(5):1258-9. PubMed ID: 10223946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
